Table 1 Comparison of Clinicopathological Characteristics in mCRC Patients with High and Those with Low PRTN3 Levels

Age (years)

67.5 [57.25, 76.25]

66 [55.5, 74.0]

0.593

Sex (male/female)

15/19

26/19

0.229

WBC (/µl)

6395 [4740, 7925]

7290 [5480, 8410]

0.160

Neutrophil count (/µl)

4133 [2803, 5279]

5011 [3593, 6682]

0.089

CEA level (ng/ml)

35.35 [12.95, 90.7]

51.8 [11.4, 331.7]

0.392

CA19-9 level (U/ml)

49.85 [10.6, 485.0]

66.2 [17.9, 260.8]

0.628

Tumor location (right/left)

13/21

21/24

0.454

T category (1/2/3/4)

0/1/11/22

0/1/22/22

0.337

N category (0/1/2/3)

6/15/8/5

11/13/12/9

0.559

Metastasis

M1 (a/ b/c)

21/5/2

20/10/7

0.181

H (0/1/2/3)

11/11/9/3

14/13/11/7

0.847

PUL (0/1/2/3)

25/5/4/0

30/7/7/1

0.778

P (0/1/2/3)

26/2/3/3

30/3/6/6

0.808

Histological grade (un-/differentiated)

5/29

5/40

0.634

RAS (mutant/wild)

12/22

23/21

0.270

Chemotherapy

 1st line (singlet/doublet/triplet)

7/27/0

9/34/2

0.310

 Fluorouracil (+/-)

34/0

45/0

-

 Oxaliplatin (+/-)

28/6

34/11

0.467

 Irinotecan (+/-)

0/34

4/41

0.074

 Anti-VEGF antibody (Bev) (+/-)

10/24

19/26

0.240

 Anti-EGFR antibody (+/-)

14/20

11/34

0.114

 Number of regimens (1/2/3-)

13/10/11

21/13/11

0.685

Operation

 Primary resection (+/-)

29/5

38/7

0.917

 Metastasis resection (+/-)

20/14

24/21

0.626

 Radical resection (R0, 1/R2, unresected-)

17/17

19/26

0.492